Terms: = Lymphoma AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
79 results:
1. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell lymphoma: Data from the First-in-Human Phase I Study.
Song Y; Jin Z; Li ZM; Liu Y; Li L; He C; Su H; Zhou H; Li K; Hao S; Zuo X; Wu J; Li D; Wu M; Sun X; Qi J; Cai Z; Li Z; Li Y; Huang Y; Shen J; Xiao Z; Zhu J
Clin Cancer Res; 2024 Apr; 30(7):1248-1255. PubMed ID: 38190117
[TBL] [Abstract] [Full Text] [Related]
2.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
3. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis.
Sato S; Ishii M; Tachibana K; Furukawa Y; Toyota T; Kinoshita S; Azusawa Y; Ando J; Ando M
Exp Hematol; 2024 Feb; 130():104132. PubMed ID: 38029851
[TBL] [Abstract] [Full Text] [Related]
4. Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p.
Lu S; Zeng L; Mo G; Lei D; Li Y; Ou G; Wu H; Sun J; Rong C; He S; Zhong D; Ke Q; Zhang Q; Tan X; Cen H; Xie X; Liao C
PLoS One; 2023; 18(11):e0294729. PubMed ID: 37988356
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of dihydropyridinone derivative as a covalent ezh2 degrader.
Zhou B; Wang B; Zou F; Mei H; Liu Q; Qi S; Wang W; Jin R; Wang A; Chen Y; Liu F; Wang W; Liu J; Liu Q
Eur J Med Chem; 2023 Dec; 261():115825. PubMed ID: 37826933
[TBL] [Abstract] [Full Text] [Related]
6. TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and ezh2 dependence.
Wu G; Yoshida N; Liu J; Zhang X; Xiong Y; Heavican-Foral TB; Mandato E; Liu H; Nelson GM; Yang L; Chen R; Donovan KA; Jones MK; Roshal M; Zhang Y; Xu R; Nirmal AJ; Jain S; Leahy C; Jones KL; Stevenson KE; Galasso N; Ganesan N; Chang T; Wu WC; Louissaint A; Debaize L; Yoon H; Dal Cin P; Chan WC; Ho Sui SJ; Ng SY; Feldman AL; Horwitz SM; Adelman K; Fischer ES; Chen CW; Weinstock DM; Brown M
Sci Transl Med; 2023 Sep; 15(714):eadi7244. PubMed ID: 37729434
[TBL] [Abstract] [Full Text] [Related]
7. ezh2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
[TBL] [Abstract] [Full Text] [Related]
8. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract] [Full Text] [Related]
9. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma.
Özçalımlı A; Erdoğdu İH; Turgutkaya A; Yavaşoğlu İ; Döger FK; Bolaman AZ
Int J Lab Hematol; 2023 Jun; 45(3):310-316. PubMed ID: 36576110
[TBL] [Abstract] [Full Text] [Related]
10. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract] [Full Text] [Related]
11. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract] [Full Text] [Related]
12. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract] [Full Text] [Related]
13. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
[TBL] [Abstract] [Full Text] [Related]
14. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
Wang X; Hong Y; Meng S; Gong W; Ren T; Zhang T; Liu X; Li L; Qiu L; Qian Z; Zhou S; Zhao M; Zhai Q; Meng B; Ren X; Zhang H; Wang X
Clin Immunol; 2022 Oct; 243():109105. PubMed ID: 36055572
[TBL] [Abstract] [Full Text] [Related]
15. CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.
Maciel ALT; Wolch K; Emerenciano M; Mansur MB
Genes Chromosomes Cancer; 2022 Jul; 61(7):437-442. PubMed ID: 35253299
[TBL] [Abstract] [Full Text] [Related]
16. SOX8 Affects Tumoral SPARC Expression by Regulating ezh2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.
Yuan S; Xu J; Zhou B; Zhou Y; Lang M; Cao J; Liu Z; Yang S; Gao S; Hao J
Int J Biol Sci; 2022; 18(3):911-922. PubMed ID: 35173526
[TBL] [Abstract] [Full Text] [Related]
17. High grade B-cell lymphoma with
Ferrari A; Arniani S; Crescenzi B; Ascani S; Flenghi L; Pierini V; Moretti M; Beacci D; Romoli S; Bardelli V; Calistri D; Martinelli G; Mecucci C; La Starza R
Leuk Lymphoma; 2022 Jun; 63(6):1356-1362. PubMed ID: 35045798
[TBL] [Abstract] [Full Text] [Related]
18. Histone Modifications and Their Targeting in Lymphoid Malignancies.
Fernández-Serrano M; Winkler R; Santos JC; Le Pannérer MM; Buschbeck M; Roué G
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008680
[TBL] [Abstract] [Full Text] [Related]
19. Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Rai S; Inoue H; Sakai K; Hanamoto H; Matsuda M; Maeda Y; Haeno T; Watatani Y; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Espinoza JL; Morita Y; Tanaka H; Ashida T; Tatsumi Y; Nishio K; Matsumura I
Cancer Sci; 2022 Feb; 113(2):660-673. PubMed ID: 34837284
[TBL] [Abstract] [Full Text] [Related]
20. Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor prognosis in Patients with Primary Central Nervous System lymphoma.
Kim HG; Kim MS; Lee YS; Lee EH; Kim DC; Lee SH; Kim YZ
Cancer Res Treat; 2022 Jul; 54(3):690-708. PubMed ID: 34793663
[TBL] [Abstract] [Full Text] [Related]
[Next]
